Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 3
1989 3
1990 4
1991 3
1993 3
1994 1
1995 2
1996 3
1997 13
1998 18
1999 34
2000 50
2001 31
2002 42
2003 36
2004 35
2005 36
2006 45
2007 48
2008 57
2009 55
2010 56
2011 47
2012 52
2013 53
2014 55
2015 49
2016 45
2017 47
2018 41
2019 38
2020 42
2021 29
2022 29
2023 42
2024 34
2025 32
2026 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,108 results

Results by year

Filters applied: . Clear all
Page 1
Ropinirole.
[No authors listed] [No authors listed] 2024 Feb 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2024 Feb 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000578 Free Books & Documents. Review.
No information is available on the use of ropinirole during breastfeeding, but it suppresses serum prolactin and may interfere with breastfeeding. ...
No information is available on the use of ropinirole during breastfeeding, but it suppresses serum prolactin and may interfere with b …
Comparison of pramipexole versus ropinirole in the treatment of Parkinson's disease.
Gencler OS, Oztekin N, Oztekin MF. Gencler OS, et al. Ideggyogy Sz. 2022 Jan 30;75(1-02):39-49. doi: 10.18071/isz.75.0039. Ideggyogy Sz. 2022. PMID: 35112520 Free article. Clinical Trial. English.
Dopamine agonist monotherapy and levodopa add-on therapy patients were randomized into two groups to receive either pramipexole or ropinirole. The maximum daily dosages of pramipexole and ropinirole were 4.5 mg and 24 mg respectively. ...CONCLUSION: This study suppo …
Dopamine agonist monotherapy and levodopa add-on therapy patients were randomized into two groups to receive either pramipexole or ropini …
Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent.
Fujimori K, Ishikawa M, Otomo A, Atsuta N, Nakamura R, Akiyama T, Hadano S, Aoki M, Saya H, Sobue G, Okano H. Fujimori K, et al. Nat Med. 2018 Oct;24(10):1579-1589. doi: 10.1038/s41591-018-0140-5. Epub 2018 Aug 20. Nat Med. 2018. PMID: 30127392
We further evaluated multiple-phenotype rescue of these subclassified SALS models using agents selected from non-SOD1 FALS models, and identified ropinirole as a potential therapeutic candidate. Integration of the datasets acquired in this study permitted the visualization …
We further evaluated multiple-phenotype rescue of these subclassified SALS models using agents selected from non-SOD1 FALS models, and ident …
Phase 1/2a clinical trial in ALS with ropinirole, a drug candidate identified by iPSC drug discovery.
Morimoto S, Takahashi S, Ito D, Daté Y, Okada K, Kato C, Nakamura S, Ozawa F, Chyi CM, Nishiyama A, Suzuki N, Fujimori K, Kondo T, Takao M, Hirai M, Kabe Y, Suematsu M, Jinzaki M, Aoki M, Fujiki Y, Sato Y, Suzuki N, Nakahara J; Pooled Resource Open-Access ALS Clinical Trials Consortium; Okano H. Morimoto S, et al. Cell Stem Cell. 2023 Jun 1;30(6):766-780.e9. doi: 10.1016/j.stem.2023.04.017. Cell Stem Cell. 2023. PMID: 37267913 Free article. Clinical Trial.
iPSC-based drug discovery led to a phase 1/2a trial of ropinirole in ALS. 20 participants with sporadic ALS received ropinirole or placebo for 24 weeks in the double-blind period to evaluate safety, tolerability, and therapeutic effects. ...However, in the open-labe …
iPSC-based drug discovery led to a phase 1/2a trial of ropinirole in ALS. 20 participants with sporadic ALS received ropinirole …
Dopamine agonists.
Factor SA. Factor SA. Med Clin North Am. 1999 Mar;83(2):415-43, vi-vii. doi: 10.1016/s0025-7125(05)70112-7. Med Clin North Am. 1999. PMID: 10093586 Review.
With the approval of two new agents in 1997, the number available in the United States is up to four; bromocriptine, pergolide, pramipexole, ropinirole. These agents differ in dopamine receptor affinities and chemical structure, which, in turn, may possibly result in diffe …
With the approval of two new agents in 1997, the number available in the United States is up to four; bromocriptine, pergolide, pramipexole, …
Clinical pharmacokinetics of ropinirole.
Kaye CM, Nicholls B. Kaye CM, et al. Clin Pharmacokinet. 2000 Oct;39(4):243-54. doi: 10.2165/00003088-200039040-00001. Clin Pharmacokinet. 2000. PMID: 11069211 Review.
Ropinirole is a selective non-ergoline dopamine D2 receptor agonist indicated for use in treating Parkinson's disease. ...There is no obvious plasma concentration-effect relationship for ropinirole....
Ropinirole is a selective non-ergoline dopamine D2 receptor agonist indicated for use in treating Parkinson's disease. ...There is no …
[Ropinirole Hydrochloride for ALS].
Takahashi S, Morimoto S, Fukushima K, Nakahara J, Okano H. Takahashi S, et al. Brain Nerve. 2019 Nov;71(11):1279-1288. doi: 10.11477/mf.1416201438. Brain Nerve. 2019. PMID: 31722314 Clinical Trial. Japanese.
We next searched for effective drugs capable of slowing the progression of ALS using a drug library of 1232 existing compounds and discovered that ropinirole hydrochloride prevented MN death. In December 2018, we started an investigator-initiated clinical trial testing …
We next searched for effective drugs capable of slowing the progression of ALS using a drug library of 1232 existing compounds and discovere …
Ropinirole therapy for Parkinson's disease.
Pahwa R, Lyons KE, Hauser RA. Pahwa R, et al. Expert Rev Neurother. 2004 Jul;4(4):581-8. doi: 10.1586/14737175.4.4.581. Expert Rev Neurother. 2004. PMID: 15853577 Review.
When used as monotherapy in early Parkinson's disease, ropinirole improves signs and symptoms of the disorder. When used as an adjunct to levodopa in advanced Parkinson's disease patients with motor fluctuations, ropinirole reduces off time and allows a reduction of …
When used as monotherapy in early Parkinson's disease, ropinirole improves signs and symptoms of the disorder. When used as an adjunc …
Ropinirole Functions Through a Dopamine Receptor D2-Independent Mechanism to Ameliorate Amyotrophic Lateral Sclerosis Phenotypes in TARDBP-Mutant iPSC-Derived Motor Neurons.
Asano H, Kawaguchi T, Kato C, Morimoto S, Yano M, Minaguchi M, Yasuda D, Fukushima K, Okano H. Asano H, et al. J Neurochem. 2025 Aug;169(8):e70183. doi: 10.1111/jnc.70183. J Neurochem. 2025. PMID: 40826812 Free PMC article.
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by motor neuron (MN) degeneration. Ropinirole hydrochloride (ROPI), a dopamine receptor D2 (DRD2) agonist, was identified through phenotypic screening of MNs derived from patient-d …
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by motor neuron (MN) degeneration. Ropinirol …
Calming restless legs.
Silber MH. Silber MH. Sleep. 2004 Aug 1;27(5):839-41. Sleep. 2004. PMID: 15453538 No abstract available.
1,108 results